HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karim Lebtahi Selected Research

N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicin

7/2004CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
4/2002CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karim Lebtahi Research Topics

Disease

2Neoplasms (Cancer)
07/2004 - 04/2002
1Neoplasm Metastasis (Metastasis)
07/2004
1Carcinoma (Carcinomatosis)
07/2004

Drug/Important Bio-Agent (IBA)

2N- (succinyl- beta- alanyl- L- leucyl- L- alanyl- L- leucyl)doxorubicinIBA
07/2004 - 04/2002
2ProdrugsIBA
07/2004 - 04/2002
2Doxorubicin (Adriamycin)FDA LinkGeneric
07/2004 - 04/2002

Therapy/Procedure

1Aftercare (After-Treatment)
04/2002
1Therapeutics
04/2002